Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study - Summary - MDSpire
Advertisement
Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study
To clarify the distribution and diagnostic yields of systematic biopsy (SB) for detecting clinically significant prostate cancer (csPCA) during initial prostate biopsy.
Key Findings:
PCA was detected in 71.8% of patients, with csPCA prevalence at 65.6%.
The combined approach (CB) showed significantly higher CDR for PCA and csPCA compared to TB and SB, indicating its superior diagnostic value.
Systematic biopsy (SB) detected more nsPCA than TB, but differences were not statistically significant.
Interpretation:
The combined approach of MRI-targeted and systematic biopsy improves detection rates of clinically significant prostate cancer, addressing limitations of MRI-only pathways and enhancing patient management.
Limitations:
The study is retrospective and conducted at a single center, which may limit generalizability to broader populations.
Uncertainty in tumor grading persists in one-third of men despite combined biopsy approaches, which may impact treatment decisions.
Conclusion:
The findings support the use of combined biopsy methods to enhance detection of clinically significant prostate cancer, although further research is needed to clarify the role of systematic biopsy and its impact on patient outcomes.
by Philipp Krausewitz, Dorothea Fostitsch, Richard Weiten, Niklas Kluemper, Johannes Stein, Julian Luetkens, Glen Kristiansen, Jörg Ellinger, Manuel Ritter
